Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | FABP7 | O15540 | 3/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.35 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116790 | 0.87 | PDE3B (0.37) | BRD4JAK3PDE3BPDE3AMAPK14 | |
| SCHEMBL7126174 | 0.81 | QDPR (0.42) | BRD4TBK1 | |
| SCHEMBL7121304 | 0.76 | CCNT1 (0.40) | KIT | |
| SCHEMBL7123785 | 0.76 | MEN1 (0.41) | — | |
| SCHEMBL7121302 | 0.74 | NAMPT (0.34) | — | |
| SCHEMBL7122721 | 0.73 | TRPV1 (0.40) | — | |
| SCHEMBL7118661 | 0.72 | NAMPT (0.37) | — | |
| SCHEMBL8643572 | 0.71 | ADRB1 (0.40) | — | |
| SCHEMBL8311721 | 0.71 | F2 (0.33) | — | |
| SCHEMBL7118393 | 0.70 | NAMPT (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | SYNGENTA LIMITED (GB) | 2003-09-04 | — | — | US | claimed |
| EP-0912561-B1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2002-12-04 | — | — | EP | claimed |
| EP-0912561-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 1999-05-06 | — | — | EP | claimed |
| WO-1997043280-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1997-11-20 | — | — | WO | claimed |
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | SYNGENTA LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-0912561-B1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-6350775-B1 | AGAINST GRAMPOSITIVE BACTERIA | ZENECA LIMITED (GB) | 2002-02-26 | — | — | US | disclosed |
| US-6110936-A | A BACTERICIDE TREATING A BACTERIAL INFECTION IN A WARM BLOODED ANIMAL | ZENECA LIMITED (GB) | 2000-08-29 | — | — | US | disclosed |
| EP-0912561-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997043280-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | CBR1, CBR3, CYP8B1 | BRD4 2260/4885FABP7 3212/4885FABP5 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.